Therapeutic bacteriophage compositions
The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.
1. A bacteriophage composition comprising at least two bacteriophages selected from Sa87, J-Sa36, and Sa83.
2. The bacteriophage composition of claim 1 , comprising purified bacteriophages Sa87, J-Sa36, and Sa83.
3. A bacteriophage composition consisting essentially of Sa87, J-Sa36, and Sa83.
4. The bacteriophage composition of claim 1 , further comprising an antibiotic.
5. The bacteriophage composition of claim 1 , further comprising a pharmaceutically acceptable carrier, diluent, excipient or combinations thereof.
6. The bacteriophage composition of claim 2 , wherein the composition comprises 1×10 11 PFU/mL per phage.
7. The bacteriophage composition of claim 6 , wherein the composition has a final endotoxin level less than 1000 EU/mL.
8. The composition of claim 7 , wherein the composition is diluted 1:10.
9. The composition of claim 7 , wherein the composition is diluted 1:100.
10. The composition of claim 1 , wherein the composition is administered to a mammal in a dosage range between about 1×10 7 to about 1×10 11 PFU of each phage at least once daily.
11. A bacteriophage composition comprising two or more purified bacteriophage populations selected from Sa87, J-Sa36, and Sa83.
12. The bacteriophage composition of claim 11 , further comprising an antibiotic.
13. The bacteriophage composition of claim 11 , further comprising a pharmaceutically acceptable carrier, diluent, excipient or combinations thereof.
14. The bacteriophage composition of claim 11 , wherein the composition comprises 1×10 11 PFU/mL per phage.
15. The bacteriophage composition of claim 14 , wherein the composition has a final endotoxin level less than 1000 EU/mL.
16. The composition of claim 15 , wherein the composition is diluted 1:10.
17. The composition of claim 15 , wherein the composition is diluted 1:100.
18. The composition of claim 15 , wherein the composition is administered to a mammal in a dosage range between about 1×10 7 to about 1×10 11 PFU of each phage at least once daily.
19. A kit comprising:
a. a bacteriophage composition according to claim 1 ; and
b. instructions for use of same.
20. The kit of claim 19 , further comprising an antibiotic and instructions for use of same in combination with the bacteriophage composition.
21. The kit of claim 20 , wherein said instructions are for use of same in treating a Staphylococcus aureus infection.
22. The kit of claim 21 , wherein the Staphylococcus aureus infection is a pulmonary infection.